The Center for Biosimilars recaps the the top 5 articles for the week of December 18, 2017.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 18.
Number 5: A newly published study shows that adalimumab is effective in treating stricturing Crohn disease.
Number 4: Mylan announced that the US Patent Trial and Appeal Board has instituted inter partes review proceedings on all claims against 2 patents covering Sanofi’s Lantus.
Number 3: Tax disclosures show that industry group PhRMA spent millions on lobbyists, politicians, and patient groups in 2016.
Number 2: Attorney Kevin Nelson, partner at Schiff Hardin, explained the impact that the federal circuit’s ruling in Amgen v Sandoz will have on biosimilar developers.
Number 1: The FDA has accepted for review Samsung Bioepis’ Biologics License Application for SB3, a proposed trastuzumab biosimilar.
Finally, last week, our e-newsletter asked whether you think that the FDA has become more lenient in approving drugs under current leadership. To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.